CORRELATION BETWEEN ANTENATAL CORTICOSTEROID USAGE AND PERINATAL DEATH IN PRETERM DELIVERIES AT A TERTIARY CARE CENTRE
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 3, Pages 12164-12173
AbstractAim: The main objectives of this study were to determine whether prenatal exposure to corticosteroids (ACS) was associated with lower rates of perinatal mortality (the primary outcome) and other harmful perinatal outcomes. The primary outcome of this study was perinatal mortality. Secondary outcomes included stillbirth, early neonatal mortality, an APGAR score of less than seven at five minutes, neonatal sepsis, and respiratory distress syndrome.
Materials and Methods: Each premature baby delivered between 24 and 34 weeks of gestation during the research period was included in the study population. There were 280 premature babies delivered in all. The participant's medical records provided us with sociodemographic and health information.
Results: 35.7% of the pregnant women between weeks 24 and 34 received at least one dosage of ACS. Compared to infants that hadn't been exposed to ACS, those who had experienced a lower rate of perinatal mortality (13.77%). (28.38 percent). An analysis of multiple variables found that newborns exposed to ACS had a lower risk of dying throughout the perinatal period (aRR 0.31). (95 % CI: 0.27–0.34) Of the sample, just one-third received ACS. The following factors were linked to the use of ACS: mother education, antenatal care attendance more than three times, gestational age measuring method, maternal infection, exposure to antibiotics while pregnant, delivery method, and level of healthcare facility.
Conclusion: Preterm newborns that received ACS had a considerably lower risk of perinatal mortality. Yet approximately a third of the women who qualified for ACS received it, showing low utilisation of ACS. In the current study, ACS utilisation was found to be poor for a variety of reasons.
- Article View: 48
- PDF Download: 40